ArticleCureus2025
Immunotherapy-Based Combination Therapy for the Successful Treatment of Coexisting Primary and Axillary Accessory Breast Cancers: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accessory breast cancer is a relatively rare condition, and to our knowledge, no previous reports have described synchronous ipsilateral cancers of the breast and the axillary accessory breast. We report a unique case involving a 70-year-old female patient with luminal A subtype breast cancer and triple-negative accessory breast cancer. The axillary tumor, which had become ulcerative and exudative, was diagnosed as an accessory breast cancer with high Programmed Cell Death Ligand 1 (PD-L1) expression. Treatment with immune checkpoint inhibitors targeting PD-L1 was effective. This case highlights the clinical importance of considering accessory breast cancer as a distinct entity and demonstrates the potential utility of immunotherapy in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.